Data-driven translational prostate cancer research: from biomarker discovery to clinical decision.

Journal: Journal of translational medicine
Published Date: Mar 7, 2020

Abstract

Prostate cancer (PCa) is a common malignant tumor with increasing incidence and high heterogeneity among males worldwide. In the era of big data and artificial intelligence, the paradigm of biomarker discovery is shifting from traditional experimental and small data-based identification toward big data-driven and systems-level screening. Complex interactions between genetic factors and environmental effects provide opportunities for systems modeling of PCa genesis and evolution. We hereby review the current research frontiers in informatics for PCa clinical translation. First, the heterogeneity and complexity in PCa development and clinical theranostics are introduced to raise the concern for PCa systems biology studies. Then biomarkers and risk factors ranging from molecular alternations to clinical phenotype and lifestyle changes are explicated for PCa personalized management. Methodologies and applications for multi-dimensional data integration and computational modeling are discussed. The future perspectives and challenges for PCa systems medicine and holistic healthcare are finally provided.

Authors

  • Yuxin Lin
    School of Computer and Communication Engineering, University of Science and Technology Beijing, Beijing, China.
  • Xiaojun Zhao
    Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Zhijun Miao
    Department of Urology, Suzhou Dushuhu Public Hospital, Suzhou, 215123, China.
  • Zhixin Ling
    Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Xuedong Wei
    Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Jinxian Pu
    Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
  • Jianquan Hou
    1 Department of Urology, First Affiliated Hospital of Soochow University, Suzhou, China.
  • Bairong Shen
    Institute of Systems Genetics, Department of Critical Care Medicine, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, China.

Keywords

External Resources

Popular Topics
Recent Journals